|
Combination immunotherapy selection for non-PD-1 axis driven tumors. |
|
|
|
|
Stock and Other Ownership Interests - OmniSeq |
Consulting or Advisory Role - NanoString Technologies |
Patents, Royalties, Other Intellectual Property - OmniSeq (Inst) |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
Patents, Royalties, Other Intellectual Property - OmniSeq (Inst) |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
Patents, Royalties, Other Intellectual Property - OmniSeq (Inst) |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
Patents, Royalties, Other Intellectual Property - OmniSeq (Inst) |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
|
|
|
Stock and Other Ownership Interests - OmniSeq; Trinds; Trinds (I) |
Consulting or Advisory Role - Agada Biosciences (I); Soligenix (I) |
Patents, Royalties, Other Intellectual Property - Thermo Fisher Scientific (Inst) |
|
Antonios Papanicolau-Sengos |
No Relationships to Disclose |
|
|
Employment - Boehringer Ingelheim (I); OmniSeq |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
Patents, Royalties, Other Intellectual Property - OmniSeq (Inst) |